Expert Opinion on Investigational Drugs · 1997 · 31 citations · 17 references
MedicinePharmacologyPharmacotherapyAndrologyNeuropharmacologyPharmacodynamicsErectile DysfunctionPenile DisordersSexual DysfunctionCyclic Guanosine Monophosphate PathwayCyclic Guanosine Monophosphate SignalingNitric OxidePde5 InhibitorsPhosphodiesterase InhibitionPhosphodiesterase RegulationPhosphodiesterase Type 5 Inhibitor TherapyPhosphodiesterase Type 5 Inhibitors
Penile erection is mediated by nitric oxide (NO) and its second messenger cyclic guanosine monophosphate (cGMP). The activity of cGMP is modulated by the enzyme phosphodiesterase (PDE). The most important physiological isoform of the enzyme in the penis is PDE5. Sildenafil is a specific inhibitor of this enzyme which potentiates nitrergic cavernosal relaxation in vitro and in animals. Clinical studies suggest that it is effective in the treatment of male erectile dysfunction (MED), which would make it the first orally active therapy for this condition.
17
Sildenafil, a novel effective oral therapy for male erectile dysfunction
Mitra Boolell, S Gepi-Attee, J C Gingell et al. · British Journal of Urology · 1996 · 576 citations
THE EPIDEMIOLOGY OF ERECTILE DYSFUNCTION
Alexandru E. Benet, Arnold Melman · Urologic Clinics of North America · 1995 · 359 citations
DOUBLE-BLIND TRIAL OF YOHIMBINE IN TREATMENT OF PSYCHOGENIC IMPOTENCE
Kelly Reid, Álvaro Morales, Cynthia J. Harris et al. · The Lancet · 1987 · 258 citations
Jamie Y. Jeremy, Stephen A. Ballard, A.M. Naylor et al. · British Journal of Urology · 1997 · 250 citations